Knight Therapeutics Inc. (TSE:GUD – Get Free Report) traded up 0.9% during trading on Monday . The company traded as high as C$9.87 and last traded at C$9.82. 52,009 shares traded hands during mid-day trading, a decline of 47% from the average daily volume of 97,584 shares. The stock had previously closed at C$9.73.
Wall Street Analysts Forecast Growth
Separately, Canaccord Genuity Group set a C$9.50 target price on Knight Therapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of C$9.50.
Get Our Latest Stock Report on Knight Therapeutics
Knight Therapeutics Stock Performance
Knight Therapeutics (TSE:GUD – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported C$0.13 earnings per share for the quarter. Knight Therapeutics had a net margin of 1.10% and a return on equity of 0.73%. The company had revenue of C$147.59 million for the quarter. On average, analysts forecast that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.
Knight Therapeutics Company Profile
Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.
Further Reading
- Five stocks we like better than Knight Therapeutics
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
